Characterizing AAV Aggregates with Subvisible Particle Analysis

Significance of the topic

Subvisible particles in viral vector formulations, such as adeno-associated virus (AAV) preparations, are critical quality attributes because they can compromise safety and efficacy. Particles in the ~1 μm to 100 μm range may not be detected by routine size-exclusion chromatography (SEC) or dynamic light scattering (DLS), yet can contribute to immunogenicity and aggregation-driven instability. Practical constraints in gene‑therapy development — limited sample volumes and numerous formulation variables — demand sensitive, low‑consumption methods capable of high‑throughput characterization to support formulation optimization and quality control.

Goals and study overview

The application note demonstrates the use of a backgrounded membrane imaging (BMI) platform (the Aura System) to detect, image, count, size, and characterize subvisible aggregates in AAV samples with minimal sample consumption. The objectives are to show that BMI-based analysis: (1) captures particles missed by SEC/DLS, (2) operates with microliter-scale samples, (3) supports multi‑condition experiments in a 96‑well format, and (4) detects changes in particle populations induced by stress or formulation variables.

Methodology

The experimental approach relies on automated membrane microscopy (BMI) to trap particulate material on a membrane and produce high‑contrast images for individual particle analysis. Key methodological features include:

• Very low sample volume per analysis (≈5 μL), minimizing consumption of precious viral material.
• Automated, plate‑based workflow (up to 96 samples) for parallel testing of conditions such as buffer ionic strength, excipients, and stressors (freeze–thaw cycles, elevated temperature).
• Optional fluorescence imaging to discriminate proteinaceous/capsid‑containing particles from non‑biological contaminants (glass, metal, plastic).
• Automated image analysis to deliver particle counts, size distributions, morphology descriptors, and per‑particle images for review.

Instrumentation used

The analyses were performed on the Aura System, a BMI‑based automated membrane imaging platform configured for high‑throughput particle analysis. The system operates in multiwell format and includes software capable of data visualization, per‑particle inspection, and compliance features (21 CFR Part 11 support). Optional fluorescence modules enable composition‑sensitive imaging.

Main results and discussion

Key findings reported in the note include:

• BMI detects subvisible particles in AAV samples that are not observed by SEC or are difficult to interpret by DLS, highlighting complementary information to common biophysical techniques.
• The system reliably images individual aggregates larger than ~1 μm, with demonstrated imaging of particles >5 μm and a stated working range up to 5 mm.
• Low sample requirement (≈5 μL) permits broad screening of formulation conditions and stress protocols; the 96‑well automation enables many conditions to be tested in a single run with analysis times on the order of ~1 minute per sample.
• Measured particle counts change predictably with stressors: increased freeze–thaw cycles and elevated temperature (example: heating to 60 °C) yield higher subvisible particle counts; lowering ionic strength destabilizes AAV and increases particle formation.
• Fluorescence imaging allows differentiation between capsid‑related particles and extrinsic contaminants, improving interpretability of particle populations.

Discussion points emphasize that SEC can remove or alter large aggregates during column separation and that DLS becomes unreliable in polydisperse mixtures or when larger particles dominate scattering. BMI captures insoluble aggregates that may be filtered away or overlooked by these techniques, thus providing an expanded view of formulation stability.

Benefits and practical applications

The Aura/BMI approach offers several practical advantages for viral vector development and QC:

• Minimal material consumption supports early‑stage and limited‑material workflows.
• High throughput screening capability accelerates formulation optimization and stress‑testing matrices.
• Per‑particle imagery and morphology reporting aid root‑cause analysis (e.g., distinguishing proteinaceous vs non‑protein particles).
• Broad detection range (submicron to millimeter scale) makes the method applicable across intended release and stability studies.
• Software compliance features (21 CFR Part 11) facilitate integration into regulated quality environments.

Future trends and potential uses

Adoption of automated low‑volume imaging for subvisible particle analysis is likely to expand alongside growing demands for gene‑therapy analytics. Anticipated developments and applications include:

• Integration of multi‑modal imaging (label‑free + fluorescence) with machine‑learning classifiers to automate particle type assignment and reduce manual review.
• Standardized workflows combining BMI with orthogonal biophysical assays (SEC, DLS, analytical ultracentrifugation) to produce comprehensive aggregation profiles for regulatory submissions.
• Smaller footprint, higher throughput instruments and further reductions in required sample volumes to accommodate single‑batch or scarce clinical material.
• Deployment in QC laboratories for lot release testing where minimal sample consumption and regulatory‑grade software are required.

Conclusion

BMI‑based subvisible particle analysis as implemented on the Aura System provides a rapid, low‑volume, high‑throughput approach for detecting and characterizing aggregates in AAV formulations. It complements SEC and DLS by revealing insoluble particles and provides high‑resolution images and quantitative size/count distributions that respond to stress and formulation changes. The technology is well suited to formulation screening, stability testing, and regulated environments where conserving sample and gathering per‑particle evidence are priorities.

References

1. US Food and Drug Administration. Annex 3(R1) Test for Particulate Contamination: Subvisible Particles; General Chapter Guidance for Industry. (Referenced in the source application note.)